医学
免疫系统
免疫学
抗体
乙型肝炎
乙型肝炎病毒
病毒学
肝炎
抗原
体液免疫
乙肝疫苗
乙型肝炎表面抗原
接种疫苗
免疫
作者
Ashish Kumar Vyas,Mojahidul Lslam,Garima Garg,Anirudh K. Singh,Nirupma Trehanpati
出处
期刊:Digestive Diseases
[S. Karger AG]
日期:2021-01-01
卷期号:39 (5): 516-525
摘要
BACKGROUND Chronicity or seroclearance of hepatitis B virus (HBV) antigens is determined by the host immune responses. Current approaches to treat HBV patients are based on inhibition of replication using different antivirals (nucleoside or nucleotide analogs) as monotherapy, or along with immune modulators as combination therapy is being used worldwide for reducing the viral load. Understanding the role of immune cellular therapies with currently available treatments for persistent viral-mediated responses in HBV patients is unexplored. However, the generation of antibodies against a surface (HBs) and envelop (HBe) antigen of hepatitis B remains an issue for future studies and needs to be explored. SUMMARY Humoral immunity, specifically T follicular helper (TFh) cells, may serve as a target for therapy for HBsAg seroconversion. In this review, we have been engrossed in the importance and role of the humoral immune responses in CHBV infection and vertical transmission. Key Message: TFh cells have been suggested as the potential target of immunotherapy which lead to seroconversion of HBe and HBs antigens of HBV. HBsAg seroconversion and eradication of covalently closed circular DNA are the main challenges for existing and forthcoming therapies in HBV infection.
科研通智能强力驱动
Strongly Powered by AbleSci AI